Stock SYRE SPYRE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
32.98 USD +0.92% Intraday chart for Spyre Therapeutics, Inc. -12.75% +53.25%
May. 15 Spyre Therapeutics, Inc. Announces Board Changes CI
May. 13 Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Spyre Therapeutics, Inc. Announces Board Changes
Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Spyre Therapeutics, Inc. Announces Board Changes
Spyre Therapeutics Agrees to Sell Shares in Private Placement for Expected Gross Proceeds of About $180 Million
Aeglea BioTherapeutics, Inc. will Change its Ticker to SYRE from AGLE
Aeglea BioTherapeutics Changes Name to Spyre Therapeutics; CEO Appointed
Aeglea BioTherapeutics, Inc. Appoints Cameron Turtle as Chief Executive Officer
Aeglea BioTherapeutics, Inc. Announces Executive Changes
Aeglea BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer
Aeglea BioTherapeutics Appoints Scott Burrows as CFO
Aeglea BioTherapeutics, Inc. Announces Executive Changes
Aeglea BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Aeglea BioTherapeutics Sells Rights to Investigational Metabolic Disease Treatment to Immedica Pharma; Shares Rise Pre-Bell
Aeglea BioTherapeutics, Inc. Enters into Agreement with Immedica Pharma AB
Immedica Pharma acquired global rights to pegzilarginase from Aeglea BioTherapeutics, Inc. for approximately $120 million.
Sector Update: Health Care Stocks Climb Thursday
Sector Update: Health Care
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYRE Stock
  4. News Spyre Therapeutics, Inc.
  5. Other languages